| INTRODUCTION
Toll-like receptors (TLR) play a major role in host defence by sensing distinct molecular components of bacteria, fungi and viruses. Once engaged they elicit phenotypic and functional changes in the many immune cell populations that express these receptors, stimulating innate immunity. 1, 2 TLR activation also supports the subsequent development of adaptive immunity and therefore TLR agonists can be harnessed to enhance vaccinal responses. 3 Given their ability to provide these potent immune effects, TLR agonists are currently being explored in a number of preclinical and clinical immunotherapy studies, either as vaccine adjuvants or in combination with monoclonal antibodies (mAb). 4 However, very few TLR agonists have been approved for clinical use to date with a few notable exceptions: the Mycobacterium bovis bacillus calmette-guerin and Imiquimod as monotherapies, and monophosphoryl lipid A as a vaccine component. 5 Imiquimod (Aldara â ), is a TLR7 agonist which was developed as a topical cream and approved by the FDA in 2004 for the treatment of superficial basal cell carcinoma (BCC). Although its mechanism of action is not completely understood, it is thought to exert its anti-tumour effect by inducing apoptosis of the BCC cells. 6 In a recent phase 2 study in patients with bladder cancer, Imiquimod showed clinical activity, with some complete responses. 7 Imiquimod has also been examined in combination; decreasing the number of metastases in the B16F10 melanoma model in combination with radiotherapy; suggesting that Imiquimod could serve as a radiosensitizer in melanoma patients. 8 However, topical application of Imiquimod can also induce and exacerbate autoimmune skin inflammation akin to psoriasis. [9] [10] [11] [12] In the mouse, these effects result from an influx of various L. N. Dahal and S. A. Beers share joint senior authorship of this article.
immune cells into the skin, epidermal hyperplasia and Th-17/IL-23 activation. This has led to Imiquimod-induced mouse psoriasis being widely used as an animal model in which to study autoimmune skin inflammation. 13, 14 Although Imiquimod appears to be a viable option for the treatment of superficial skin malignancies, there is a pressing need to identify, characterize and develop additional TLR agonists that provide more systemic and potent effects.
We recently examined the potential of a range of TLR agonists for their ability to activate innate immune cells, including mouse and human macrophages, to improve mAbmediated immunotherapy. 15 Although Imiquimod demonstrated some activity, it was unable to significantly augment mAb-immunotherapy. One possibility was that Imiquimod is not sufficiently potent to elicit these responses and so here we examined the potential of an alternative TLR7 agonist, 4-[6-amino-8-hydroxy-2-(2-methoxyethoxy)purin-9-ylmethyl] benzaldehyde (UC-1V150). 16 UC-1V150 is synthesized from 2,6-dichloropurine with a free aldehyde group on the benzyl moiety so that it can be coupled to auxiliary chemical entities/proteins of interest 16 and has been successfully conjugated to mAbs of clinical relevance raising the prospect of cell-targeted TLR activation. 17 To date, the therapeutic effect of UC-1V150 has only been studied in the context of infectious disease, where it was seen to stimulate murine macrophages to produce the pro-inflammatory cytokines IL-6 and IL-12 in vitro and in vivo. 16 However, the ability of this reagent to provide adjuvant effects to mAb immunotherapy remains to be explored. Here, we provide evidence that UC-1V150 potently activates macrophages, enhances engulfment of tumour cells in vitro and augments mAb-mediated target cell depletion in vivo. 
| MATERIALS AND METHODS

| Clinical samples and ethics
UC-1V150 was synthesized according to previously reported procedure 16 and retrieved as an off-white solid and reconstituted in DMSO.
| Phagocytosis assay
PBMC from leucocyte cones were purified by Lymphoprep TM (Axis-Shield) density centrifugation and cell number adjusted to a concentration of 1 9 10 7 cells/mL in RPMI 1640 conditioned with 1% Human AB serum, Penicillin, Streptomycin, L-Glutamine and Sodium pyruvate (SigmaAldrich), 2 mL/well plated in a 6-well tissue culture plate and left to incubate for 2 hours at 37°C in 5% CO 2 . Nonadherent cells were then removed and adherent cells incubated for 6 days in the presence of 100 ng/mL recombinant human (rh) M-CSF (generated in house) in RPMI 1640 containing 10% FCS, penicillin, streptomycin, L-glutamine and sodium pyruvate. Cells were fed on alternative days.
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Human monocyte-derived macrophages (hMDM) generated this way were then polarised to M1 or M2 using LPS: 50 ng/mL, recombinant human (rh) IFN-c: 2 ng/mL (Peprotech), or rhIL-4: 10 ng/mL (Peprotech), rhIL-13: 10 ng/mL (Peprotech), respectively. Alternatively, hMDM were stimulated with Imiquimod (Invivogen) or UC-1V150 at 1 lg/mL for 48 hours. Phagocytosis assays were then performed as previously described 18 with human CLL cells as targets. Phagocytic index was calculated by dividing the percentage of phagocytic macrophages under the test condition by the percentage of phagocytic macrophages seen in the unstimulated condition.
| Phenotypic analysis of macrophages and calculation of FccR activatory:inhibitory (A:I) ratio
Human and murine FccR staining was performed as described previously. 19 Fluorescently conjugated mAb were obtained from BD Biosciences, AbDSerotec, eBioscience or made in-house. hMDM were stained with anti-human CD40-Alexafluor (AF)488 (Clone ChiLob7/6), CD38-AF488 (Clone AT13/5), both in-house, and CD11b-PE (eBioscience). Murine splenocytes were stained with antimouse CD11b-PE, Ly6C-PerCpCy5.5, Ly6G-PECy7 (eBioscience), and F4/80-APC (AbD Serotec). Samples were acquired on a FACS calibur or canto II (BD Bioscience) and data analyzed with FCS express (DeNovo Software). The FccR activatory:inhibitory (A:I) ratio for hMDM was calculated as: MFI for FccRI*FccRIIA*FccRIII/FccRIIB for hMDM and FccRI*FccRIII*FccRIV/FccRII for murine macrophages) giving a value of x for NT macrophage. The results for each test condition were then divided by x so that unstimulated macrophages received a ratio of 1. Using this approach allows each FccR to contribute to the A:I ratio, regardless of the fluorochromes with which the detecting antibodies are labelled.
| In vivo B cell depletion assays
Depletion of adoptively transferred hCD20 Tg B cells was performed as described previously. 18 In brief, splenocytes from target (T) hCD20Tg and non-target (NT) wild-type mice were labelled with 5 lmol/L and 0.5 lmol/L CFSE (Invitrogen), respectively, mixed (1:1), and i.v injected into recipients (5-8 9 10 6 cells/mouse). UC-1V150 (1-10 lg)
was administered after 24 and 48 hours, followed by Ritm2a (25 lg) or isotype control. Spleens were harvested 16-20 hours after Ritm2a administration, splenocytes stained with anti-mouse CD19-APC (eBioscience) and assessed for T:NT ratio.
| Statistical analysis
Statistical analysis was performed using GraphPadPrism. To compare differences between the experimental groups, student's t tests were performed with Welch's correction; a P-value <.05 was considered significant at the 95% confidence interval. Stars denote significance as follows: *P < .05, **P < .01, ***P < .001 and ****P < .0001.
| RESULTS AND DISCUSSION
Agonists of TLR7 have previously been shown to modulate macrophage activation: The TLR7/8 agonist R-848 was shown to upregulate the activating FccR and downregulate the inhibitory FccRIIB, 20 whereas the TLR7 agonist Imiquimod has been shown to induce pro-inflammatory cytokine release. 21 However, its effects on macrophage phenotype, FccR expression and function are not known.
To assess this and compare the stimulatory potential of UC-1V150, we generated macrophages from human peripheral blood monocytes and measured their response to Imiquimod and UC-1V150 vs the archetypal M1/M2 stimuli; LPS/IFN-c and IL-4/-13, by measuring CD40 and CD38 for pro-inflammatory activation and CD11b and DC-SIGN as markers for alternative activation. UC-1V150, but not Imiquimod, showed an inflammatory profile resembling LPS/IFN-c stimulated macrophages with increases in CD40 and CD38, decreased CD11b, and no change in DC-SIGN ( Figure 1 ). In line with the inflammatory phenotypic profile observed (Figure 1 ), UC-1V150 showed an increase in the expression of activating FccRIIA and FccRIII with no change in expression of inhibitory FccRIIB (Figure 2A ) resulting in an increased A:I ratio ( Figure 2B ), greater to that achieved by LPS/IFN-c stimulation. We did not observe such profound changes in the FccR profile and A:I ratio with the Imiquimod, indicating UC-1V150 is a more potent compound.
The phenotypic and FccR changes induced by UC-1V150 were indicative of pro-inflammatory activation and therefore we assessed if these macrophages also displayed augmented functional activity in terms of their ability to phagocytose mAb-opsonized primary CLL cells (Figure 2C) by flow cytometry. We have previously demonstrated, through a variety of methods, including fluorescence imaging and confocal microscopy techniques, 18, 22 that phagocytic activity registered by flow cytometry is an accurate portrayal of macrophage engulfment of target cells rather than conjugate formation/rosetting around macrophages. Using this methodology Imiquimod treated macrophages from the majority of donors showed only a modest increase in the phagocytosis of target CLL cells, but UC-1V150 induced a more robust 1.5 fold increase in phagocytic index compared to untreated hMDM ( Figure 2D ), raising the possibility of synergistic combination with antibody therapeutics. Whilst data are presented for a single dose/concentration, prior reports 23, 24 suggest that this concentration is significantly above the ED50 for both compounds, and for UC-1V150 relatively selective for TLR7. 17 These compounds do not show major quantitative differences in potency when compared in concentration-response analysis of cellular activation or cytokine induction. Furthermore, we initially conducted a dose-response (0.1, 1 and 10 lg/mL of UC-1V150 in hMDM cultures and observed 0.1 lg/mL had minimal effect on macrophage activation, whilst 10 lg/mL was toxic to the cells [Data not shown].
After establishing the ability of UC-1V150 to modulate human macrophages in vitro both phenotypically and functionally, we asked whether such changes could be seen in vivo, in mice. We first injected mice intraperitoneally with UC-1V150 and investigated the differences in FccR expression and A:I ratio induced on splenic macrophages. Without inducing a significant influx of inflammatory myeloid cells into the spleen (Figure 3A) , UC-1V150 enhanced the levels of FccRI and -IV on splenic macrophages (Figure 3B) , culminating in an almost 4-fold increase in A:I ratio ( Figure 3C ). Using a robust, well established adoptive transfer model, 18 we then assessed the ability of UC-1V150 to augment the mAb-mediated depletion of transferred hCD20 Tg B cells. mAb-mediated depletion of hCD20 Tg B cells was also significantly enhanced by UC-1V150, both in the spleen ( Figure 3D , E) and blood of recipient mice ( Figure 3F ).
Here, we provide evidence for the ability of UC-1V150, a relatively new class of TLR7 agonist that has not been investigated in the context of mAb therapy and macrophage modulation, to augment mAb activity both in vitro and in vivo. Clearly, this has 2 important implications. First, repolarisation of macrophages to an inflammatory profile is a keenly sought goal for immunotherapy and the identification of cellular pathways and candidate drugs capable of reversing immune suppression in vivo, leading to macrophage polarisation, will allow effective manipulation of these immune effectors in disease settings. This is important in the context of macrophages, as they can express all FccR and have great potential to destroy tumours through FccR-mediated phagocytosis. 18 Second, we provide evidence that this process is mediated by FccR changes such that the A:I ratio is tipped in favour of optimal mAb therapy. FccR play a critical role in regulating immune homeostasis and their expression must be carefully modulated such that the FccR A:I ratio is appropriate, preventing unsolicited immune effects whilst permitting beneficial pro-inflammatory responses to ensue. 25 No overarching role has been ascribed to a single FccR in mediating these effector activities, but it has previously been reported that high FccRIIB expression may explain resistance to the anti-CD20 mAb rituximab; and that the composite function of the A:I ratio mirrors the efficacy of the TLR reagent in providing adjuvant effects to mAb immunotherapy. 26 So-called Danger signals provided by TLR activation enable effective FccR A:I ratio skewing, but their efficacy in vivo is limited. For instance, the TLR1/2 agonist Pam3CSK4 robustly induced favourable FccR A:I changes, inflammation and phagocytosis of target cells in vitro, but failed to achieve this in vivo. 15 Therefore, drugs such as UC-1V150 that promote appropriate FccR expression profiles in vivo, with the potential for murine to human translation raise the possibility of providing synergistic treatments with existing antibody therapeutics. However, TLR7 activation on B cells may influence selection, proliferation and diversification of the repertoire of B cells in the germinal centre, impeding the B cell tolerance checkpoints. 27, 28 Therefore, a better understanding of the interaction between the B-cell receptor (BCR) and TLR7, as well as careful modulation of their responses, is critical when identifying potential therapeutic reagents targeting TLR7 as its hyperactivation may lead to autoantibody production by BCR activated cells potentially resulting in autoimmunity. 
